Global Targeted Drugs for Multiple Myeloma Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Targeted Drugs for Multiple Myeloma Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Multiple Myeloma sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Multiple Myeloma sales for 2023 through 2029. With Targeted Drugs for Multiple Myeloma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Multiple Myeloma industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Multiple Myeloma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drugs for Multiple Myeloma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Multiple Myeloma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Multiple Myeloma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Multiple Myeloma.
The global Targeted Drugs for Multiple Myeloma market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Targeted Drugs for Multiple Myeloma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Targeted Drugs for Multiple Myeloma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Targeted Drugs for Multiple Myeloma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Targeted Drugs for Multiple Myeloma players cover Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories and Qilu Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Multiple Myeloma market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
LPI (LP Information)' newest research report, the “Targeted Drugs for Multiple Myeloma Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Multiple Myeloma sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Multiple Myeloma sales for 2023 through 2029. With Targeted Drugs for Multiple Myeloma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Multiple Myeloma industry.
This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Multiple Myeloma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drugs for Multiple Myeloma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Multiple Myeloma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Multiple Myeloma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Multiple Myeloma.
The global Targeted Drugs for Multiple Myeloma market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Targeted Drugs for Multiple Myeloma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Targeted Drugs for Multiple Myeloma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Targeted Drugs for Multiple Myeloma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Targeted Drugs for Multiple Myeloma players cover Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories and Qilu Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Multiple Myeloma market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Immunomodulator
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors (HDACI)
- Monoclonal Antibody
- Other
- Hospital
- Drug Center
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Celgene
- Exova
- Natco Pharma
- Intas Pharmaceuticals
- Indiabulls Pharmaceutical
- Cipla
- Glenmark Pharmaceuticals
- Dr Reddy's Laboratories
- Qilu Pharmaceutical
- Chia Tai-Tianqing
- Hanson Pharm
- Meidakang Huakang Pharmaceutical
- Shandong Kongfu Pharmaceutical
- J&J
- Takeda
- Amgen
- Bristol Myers Squibb
- Abbvie
- Seattle Genetics
- Karyopharm Therapeutics
- PDL BioPharma
- Roche
- Sumitomo
- Merck
- Biogen
- Schering-Plough
- Glaxo
- Chiron
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drugs for Multiple Myeloma Market Size 2018-2029
2.1.2 Targeted Drugs for Multiple Myeloma Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Targeted Drugs for Multiple Myeloma Segment by Type
2.2.1 Immunomodulator
2.2.2 Proteasome Inhibitors
2.2.3 Histone Deacetylase Inhibitors (HDACI)
2.2.4 Monoclonal Antibody
2.2.5 Other
2.3 Targeted Drugs for Multiple Myeloma Market Size by Type
2.3.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
2.4 Targeted Drugs for Multiple Myeloma Segment by Application
2.4.1 Hospital
2.4.2 Drug Center
2.4.3 Clinic
2.4.4 Other
2.5 Targeted Drugs for Multiple Myeloma Market Size by Application
2.5.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
3 TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET SIZE BY PLAYER
3.1 Targeted Drugs for Multiple Myeloma Market Size Market Share by Players
3.1.1 Global Targeted Drugs for Multiple Myeloma Revenue by Players (2018-2023)
3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2018-2023)
3.2 Global Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUGS FOR MULTIPLE MYELOMA BY REGIONS
4.1 Targeted Drugs for Multiple Myeloma Market Size by Regions (2018-2023)
4.2 Americas Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
4.3 APAC Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
4.4 Europe Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
4.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023)
5.2 Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
5.3 Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2018-2023)
6.2 APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
6.3 APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drugs for Multiple Myeloma by Country (2018-2023)
7.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drugs for Multiple Myeloma by Region (2018-2023)
8.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
8.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET FORECAST
10.1 Global Targeted Drugs for Multiple Myeloma Forecast by Regions (2024-2029)
10.1.1 Global Targeted Drugs for Multiple Myeloma Forecast by Regions (2024-2029)
10.1.2 Americas Targeted Drugs for Multiple Myeloma Forecast
10.1.3 APAC Targeted Drugs for Multiple Myeloma Forecast
10.1.4 Europe Targeted Drugs for Multiple Myeloma Forecast
10.1.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast
10.2 Americas Targeted Drugs for Multiple Myeloma Forecast by Country (2024-2029)
10.2.1 United States Targeted Drugs for Multiple Myeloma Market Forecast
10.2.2 Canada Targeted Drugs for Multiple Myeloma Market Forecast
10.2.3 Mexico Targeted Drugs for Multiple Myeloma Market Forecast
10.2.4 Brazil Targeted Drugs for Multiple Myeloma Market Forecast
10.3 APAC Targeted Drugs for Multiple Myeloma Forecast by Region (2024-2029)
10.3.1 China Targeted Drugs for Multiple Myeloma Market Forecast
10.3.2 Japan Targeted Drugs for Multiple Myeloma Market Forecast
10.3.3 Korea Targeted Drugs for Multiple Myeloma Market Forecast
10.3.4 Southeast Asia Targeted Drugs for Multiple Myeloma Market Forecast
10.3.5 India Targeted Drugs for Multiple Myeloma Market Forecast
10.3.6 Australia Targeted Drugs for Multiple Myeloma Market Forecast
10.4 Europe Targeted Drugs for Multiple Myeloma Forecast by Country (2024-2029)
10.4.1 Germany Targeted Drugs for Multiple Myeloma Market Forecast
10.4.2 France Targeted Drugs for Multiple Myeloma Market Forecast
10.4.3 UK Targeted Drugs for Multiple Myeloma Market Forecast
10.4.4 Italy Targeted Drugs for Multiple Myeloma Market Forecast
10.4.5 Russia Targeted Drugs for Multiple Myeloma Market Forecast
10.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast by Region (2024-2029)
10.5.1 Egypt Targeted Drugs for Multiple Myeloma Market Forecast
10.5.2 South Africa Targeted Drugs for Multiple Myeloma Market Forecast
10.5.3 Israel Targeted Drugs for Multiple Myeloma Market Forecast
10.5.4 Turkey Targeted Drugs for Multiple Myeloma Market Forecast
10.5.5 GCC Countries Targeted Drugs for Multiple Myeloma Market Forecast
10.6 Global Targeted Drugs for Multiple Myeloma Forecast by Type (2024-2029)
10.7 Global Targeted Drugs for Multiple Myeloma Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Celgene
11.1.1 Celgene Company Information
11.1.2 Celgene Targeted Drugs for Multiple Myeloma Product Offered
11.1.3 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Celgene Main Business Overview
11.1.5 Celgene Latest Developments
11.2 Exova
11.2.1 Exova Company Information
11.2.2 Exova Targeted Drugs for Multiple Myeloma Product Offered
11.2.3 Exova Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Exova Main Business Overview
11.2.5 Exova Latest Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
11.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Natco Pharma Main Business Overview
11.3.5 Natco Pharma Latest Developments
11.4 Intas Pharmaceuticals
11.4.1 Intas Pharmaceuticals Company Information
11.4.2 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
11.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Intas Pharmaceuticals Main Business Overview
11.4.5 Intas Pharmaceuticals Latest Developments
11.5 Indiabulls Pharmaceutical
11.5.1 Indiabulls Pharmaceutical Company Information
11.5.2 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Indiabulls Pharmaceutical Main Business Overview
11.5.5 Indiabulls Pharmaceutical Latest Developments
11.6 Cipla
11.6.1 Cipla Company Information
11.6.2 Cipla Targeted Drugs for Multiple Myeloma Product Offered
11.6.3 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Cipla Main Business Overview
11.6.5 Cipla Latest Developments
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Information
11.7.2 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
11.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Glenmark Pharmaceuticals Main Business Overview
11.7.5 Glenmark Pharmaceuticals Latest Developments
11.8 Dr Reddy's Laboratories
11.8.1 Dr Reddy's Laboratories Company Information
11.8.2 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
11.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Dr Reddy's Laboratories Main Business Overview
11.8.5 Dr Reddy's Laboratories Latest Developments
11.9 Qilu Pharmaceutical
11.9.1 Qilu Pharmaceutical Company Information
11.9.2 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Qilu Pharmaceutical Main Business Overview
11.9.5 Qilu Pharmaceutical Latest Developments
11.10 Chia Tai-Tianqing
11.10.1 Chia Tai-Tianqing Company Information
11.10.2 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
11.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Chia Tai-Tianqing Main Business Overview
11.10.5 Chia Tai-Tianqing Latest Developments
11.11 Hanson Pharm
11.11.1 Hanson Pharm Company Information
11.11.2 Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
11.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Hanson Pharm Main Business Overview
11.11.5 Hanson Pharm Latest Developments
11.12 Meidakang Huakang Pharmaceutical
11.12.1 Meidakang Huakang Pharmaceutical Company Information
11.12.2 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Meidakang Huakang Pharmaceutical Main Business Overview
11.12.5 Meidakang Huakang Pharmaceutical Latest Developments
11.13 Shandong Kongfu Pharmaceutical
11.13.1 Shandong Kongfu Pharmaceutical Company Information
11.13.2 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Shandong Kongfu Pharmaceutical Main Business Overview
11.13.5 Shandong Kongfu Pharmaceutical Latest Developments
11.14 J&J
11.14.1 J&J Company Information
11.14.2 J&J Targeted Drugs for Multiple Myeloma Product Offered
11.14.3 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 J&J Main Business Overview
11.14.5 J&J Latest Developments
11.15 Takeda
11.15.1 Takeda Company Information
11.15.2 Takeda Targeted Drugs for Multiple Myeloma Product Offered
11.15.3 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Takeda Main Business Overview
11.15.5 Takeda Latest Developments
11.16 Amgen
11.16.1 Amgen Company Information
11.16.2 Amgen Targeted Drugs for Multiple Myeloma Product Offered
11.16.3 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Amgen Main Business Overview
11.16.5 Amgen Latest Developments
11.17 Bristol Myers Squibb
11.17.1 Bristol Myers Squibb Company Information
11.17.2 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
11.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Bristol Myers Squibb Main Business Overview
11.17.5 Bristol Myers Squibb Latest Developments
11.18 Abbvie
11.18.1 Abbvie Company Information
11.18.2 Abbvie Targeted Drugs for Multiple Myeloma Product Offered
11.18.3 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Abbvie Main Business Overview
11.18.5 Abbvie Latest Developments
11.19 Seattle Genetics
11.19.1 Seattle Genetics Company Information
11.19.2 Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
11.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Seattle Genetics Main Business Overview
11.19.5 Seattle Genetics Latest Developments
11.20 Karyopharm Therapeutics
11.20.1 Karyopharm Therapeutics Company Information
11.20.2 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
11.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Karyopharm Therapeutics Main Business Overview
11.20.5 Karyopharm Therapeutics Latest Developments
11.21 PDL BioPharma
11.21.1 PDL BioPharma Company Information
11.21.2 PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
11.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 PDL BioPharma Main Business Overview
11.21.5 PDL BioPharma Latest Developments
11.22 Roche
11.22.1 Roche Company Information
11.22.2 Roche Targeted Drugs for Multiple Myeloma Product Offered
11.22.3 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Roche Main Business Overview
11.22.5 Roche Latest Developments
11.23 Sumitomo
11.23.1 Sumitomo Company Information
11.23.2 Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
11.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 Sumitomo Main Business Overview
11.23.5 Sumitomo Latest Developments
11.24 Merck
11.24.1 Merck Company Information
11.24.2 Merck Targeted Drugs for Multiple Myeloma Product Offered
11.24.3 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 Merck Main Business Overview
11.24.5 Merck Latest Developments
11.25 Biogen
11.25.1 Biogen Company Information
11.25.2 Biogen Targeted Drugs for Multiple Myeloma Product Offered
11.25.3 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Biogen Main Business Overview
11.25.5 Biogen Latest Developments
11.26 Schering-Plough
11.26.1 Schering-Plough Company Information
11.26.2 Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
11.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.26.4 Schering-Plough Main Business Overview
11.26.5 Schering-Plough Latest Developments
11.27 Glaxo
11.27.1 Glaxo Company Information
11.27.2 Glaxo Targeted Drugs for Multiple Myeloma Product Offered
11.27.3 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.27.4 Glaxo Main Business Overview
11.27.5 Glaxo Latest Developments
11.28 Chiron
11.28.1 Chiron Company Information
11.28.2 Chiron Targeted Drugs for Multiple Myeloma Product Offered
11.28.3 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.28.4 Chiron Main Business Overview
11.28.5 Chiron Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Drugs for Multiple Myeloma Market Size 2018-2029
2.1.2 Targeted Drugs for Multiple Myeloma Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Targeted Drugs for Multiple Myeloma Segment by Type
2.2.1 Immunomodulator
2.2.2 Proteasome Inhibitors
2.2.3 Histone Deacetylase Inhibitors (HDACI)
2.2.4 Monoclonal Antibody
2.2.5 Other
2.3 Targeted Drugs for Multiple Myeloma Market Size by Type
2.3.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
2.4 Targeted Drugs for Multiple Myeloma Segment by Application
2.4.1 Hospital
2.4.2 Drug Center
2.4.3 Clinic
2.4.4 Other
2.5 Targeted Drugs for Multiple Myeloma Market Size by Application
2.5.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
3 TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET SIZE BY PLAYER
3.1 Targeted Drugs for Multiple Myeloma Market Size Market Share by Players
3.1.1 Global Targeted Drugs for Multiple Myeloma Revenue by Players (2018-2023)
3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2018-2023)
3.2 Global Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TARGETED DRUGS FOR MULTIPLE MYELOMA BY REGIONS
4.1 Targeted Drugs for Multiple Myeloma Market Size by Regions (2018-2023)
4.2 Americas Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
4.3 APAC Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
4.4 Europe Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
4.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023)
5.2 Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
5.3 Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2018-2023)
6.2 APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
6.3 APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Targeted Drugs for Multiple Myeloma by Country (2018-2023)
7.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Drugs for Multiple Myeloma by Region (2018-2023)
8.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
8.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET FORECAST
10.1 Global Targeted Drugs for Multiple Myeloma Forecast by Regions (2024-2029)
10.1.1 Global Targeted Drugs for Multiple Myeloma Forecast by Regions (2024-2029)
10.1.2 Americas Targeted Drugs for Multiple Myeloma Forecast
10.1.3 APAC Targeted Drugs for Multiple Myeloma Forecast
10.1.4 Europe Targeted Drugs for Multiple Myeloma Forecast
10.1.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast
10.2 Americas Targeted Drugs for Multiple Myeloma Forecast by Country (2024-2029)
10.2.1 United States Targeted Drugs for Multiple Myeloma Market Forecast
10.2.2 Canada Targeted Drugs for Multiple Myeloma Market Forecast
10.2.3 Mexico Targeted Drugs for Multiple Myeloma Market Forecast
10.2.4 Brazil Targeted Drugs for Multiple Myeloma Market Forecast
10.3 APAC Targeted Drugs for Multiple Myeloma Forecast by Region (2024-2029)
10.3.1 China Targeted Drugs for Multiple Myeloma Market Forecast
10.3.2 Japan Targeted Drugs for Multiple Myeloma Market Forecast
10.3.3 Korea Targeted Drugs for Multiple Myeloma Market Forecast
10.3.4 Southeast Asia Targeted Drugs for Multiple Myeloma Market Forecast
10.3.5 India Targeted Drugs for Multiple Myeloma Market Forecast
10.3.6 Australia Targeted Drugs for Multiple Myeloma Market Forecast
10.4 Europe Targeted Drugs for Multiple Myeloma Forecast by Country (2024-2029)
10.4.1 Germany Targeted Drugs for Multiple Myeloma Market Forecast
10.4.2 France Targeted Drugs for Multiple Myeloma Market Forecast
10.4.3 UK Targeted Drugs for Multiple Myeloma Market Forecast
10.4.4 Italy Targeted Drugs for Multiple Myeloma Market Forecast
10.4.5 Russia Targeted Drugs for Multiple Myeloma Market Forecast
10.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast by Region (2024-2029)
10.5.1 Egypt Targeted Drugs for Multiple Myeloma Market Forecast
10.5.2 South Africa Targeted Drugs for Multiple Myeloma Market Forecast
10.5.3 Israel Targeted Drugs for Multiple Myeloma Market Forecast
10.5.4 Turkey Targeted Drugs for Multiple Myeloma Market Forecast
10.5.5 GCC Countries Targeted Drugs for Multiple Myeloma Market Forecast
10.6 Global Targeted Drugs for Multiple Myeloma Forecast by Type (2024-2029)
10.7 Global Targeted Drugs for Multiple Myeloma Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Celgene
11.1.1 Celgene Company Information
11.1.2 Celgene Targeted Drugs for Multiple Myeloma Product Offered
11.1.3 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Celgene Main Business Overview
11.1.5 Celgene Latest Developments
11.2 Exova
11.2.1 Exova Company Information
11.2.2 Exova Targeted Drugs for Multiple Myeloma Product Offered
11.2.3 Exova Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Exova Main Business Overview
11.2.5 Exova Latest Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
11.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Natco Pharma Main Business Overview
11.3.5 Natco Pharma Latest Developments
11.4 Intas Pharmaceuticals
11.4.1 Intas Pharmaceuticals Company Information
11.4.2 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
11.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Intas Pharmaceuticals Main Business Overview
11.4.5 Intas Pharmaceuticals Latest Developments
11.5 Indiabulls Pharmaceutical
11.5.1 Indiabulls Pharmaceutical Company Information
11.5.2 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Indiabulls Pharmaceutical Main Business Overview
11.5.5 Indiabulls Pharmaceutical Latest Developments
11.6 Cipla
11.6.1 Cipla Company Information
11.6.2 Cipla Targeted Drugs for Multiple Myeloma Product Offered
11.6.3 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Cipla Main Business Overview
11.6.5 Cipla Latest Developments
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Information
11.7.2 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
11.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Glenmark Pharmaceuticals Main Business Overview
11.7.5 Glenmark Pharmaceuticals Latest Developments
11.8 Dr Reddy's Laboratories
11.8.1 Dr Reddy's Laboratories Company Information
11.8.2 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
11.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Dr Reddy's Laboratories Main Business Overview
11.8.5 Dr Reddy's Laboratories Latest Developments
11.9 Qilu Pharmaceutical
11.9.1 Qilu Pharmaceutical Company Information
11.9.2 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Qilu Pharmaceutical Main Business Overview
11.9.5 Qilu Pharmaceutical Latest Developments
11.10 Chia Tai-Tianqing
11.10.1 Chia Tai-Tianqing Company Information
11.10.2 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
11.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Chia Tai-Tianqing Main Business Overview
11.10.5 Chia Tai-Tianqing Latest Developments
11.11 Hanson Pharm
11.11.1 Hanson Pharm Company Information
11.11.2 Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
11.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Hanson Pharm Main Business Overview
11.11.5 Hanson Pharm Latest Developments
11.12 Meidakang Huakang Pharmaceutical
11.12.1 Meidakang Huakang Pharmaceutical Company Information
11.12.2 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Meidakang Huakang Pharmaceutical Main Business Overview
11.12.5 Meidakang Huakang Pharmaceutical Latest Developments
11.13 Shandong Kongfu Pharmaceutical
11.13.1 Shandong Kongfu Pharmaceutical Company Information
11.13.2 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
11.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Shandong Kongfu Pharmaceutical Main Business Overview
11.13.5 Shandong Kongfu Pharmaceutical Latest Developments
11.14 J&J
11.14.1 J&J Company Information
11.14.2 J&J Targeted Drugs for Multiple Myeloma Product Offered
11.14.3 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 J&J Main Business Overview
11.14.5 J&J Latest Developments
11.15 Takeda
11.15.1 Takeda Company Information
11.15.2 Takeda Targeted Drugs for Multiple Myeloma Product Offered
11.15.3 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Takeda Main Business Overview
11.15.5 Takeda Latest Developments
11.16 Amgen
11.16.1 Amgen Company Information
11.16.2 Amgen Targeted Drugs for Multiple Myeloma Product Offered
11.16.3 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Amgen Main Business Overview
11.16.5 Amgen Latest Developments
11.17 Bristol Myers Squibb
11.17.1 Bristol Myers Squibb Company Information
11.17.2 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
11.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Bristol Myers Squibb Main Business Overview
11.17.5 Bristol Myers Squibb Latest Developments
11.18 Abbvie
11.18.1 Abbvie Company Information
11.18.2 Abbvie Targeted Drugs for Multiple Myeloma Product Offered
11.18.3 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Abbvie Main Business Overview
11.18.5 Abbvie Latest Developments
11.19 Seattle Genetics
11.19.1 Seattle Genetics Company Information
11.19.2 Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
11.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Seattle Genetics Main Business Overview
11.19.5 Seattle Genetics Latest Developments
11.20 Karyopharm Therapeutics
11.20.1 Karyopharm Therapeutics Company Information
11.20.2 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
11.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Karyopharm Therapeutics Main Business Overview
11.20.5 Karyopharm Therapeutics Latest Developments
11.21 PDL BioPharma
11.21.1 PDL BioPharma Company Information
11.21.2 PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
11.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 PDL BioPharma Main Business Overview
11.21.5 PDL BioPharma Latest Developments
11.22 Roche
11.22.1 Roche Company Information
11.22.2 Roche Targeted Drugs for Multiple Myeloma Product Offered
11.22.3 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 Roche Main Business Overview
11.22.5 Roche Latest Developments
11.23 Sumitomo
11.23.1 Sumitomo Company Information
11.23.2 Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
11.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 Sumitomo Main Business Overview
11.23.5 Sumitomo Latest Developments
11.24 Merck
11.24.1 Merck Company Information
11.24.2 Merck Targeted Drugs for Multiple Myeloma Product Offered
11.24.3 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 Merck Main Business Overview
11.24.5 Merck Latest Developments
11.25 Biogen
11.25.1 Biogen Company Information
11.25.2 Biogen Targeted Drugs for Multiple Myeloma Product Offered
11.25.3 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Biogen Main Business Overview
11.25.5 Biogen Latest Developments
11.26 Schering-Plough
11.26.1 Schering-Plough Company Information
11.26.2 Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
11.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.26.4 Schering-Plough Main Business Overview
11.26.5 Schering-Plough Latest Developments
11.27 Glaxo
11.27.1 Glaxo Company Information
11.27.2 Glaxo Targeted Drugs for Multiple Myeloma Product Offered
11.27.3 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.27.4 Glaxo Main Business Overview
11.27.5 Glaxo Latest Developments
11.28 Chiron
11.28.1 Chiron Company Information
11.28.2 Chiron Targeted Drugs for Multiple Myeloma Product Offered
11.28.3 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
11.28.4 Chiron Main Business Overview
11.28.5 Chiron Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Drugs for Multiple Myeloma Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Immunomodulator
Table 3. Major Players of Proteasome Inhibitors
Table 4. Major Players of Histone Deacetylase Inhibitors (HDACI)
Table 5. Major Players of Monoclonal Antibody
Table 6. Major Players of Other
Table 7. Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 9. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 10. Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 11. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 12. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 13. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2018-2023) & ($ Millions)
Table 14. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player (2018-2023)
Table 15. Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
Table 16. Targeted Drugs for Multiple Myeloma Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Targeted Drugs for Multiple Myeloma Market Size by Regions 2018-2023 & ($ Millions)
Table 20. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Regions (2018-2023)
Table 21. Global Targeted Drugs for Multiple Myeloma Revenue by Country/Region (2018-2023) & ($ millions)
Table 22. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Country/Region (2018-2023)
Table 23. Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023) & ($ Millions)
Table 24. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2018-2023)
Table 25. Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 26. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 27. Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 28. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 29. APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2018-2023) & ($ Millions)
Table 30. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)
Table 31. APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 32. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 33. APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 34. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 35. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023) & ($ Millions)
Table 36. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2018-2023)
Table 37. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 38. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 39. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 40. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 41. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Region (2018-2023) & ($ Millions)
Table 42. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)
Table 43. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 45. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 47. Key Market Drivers & Growth Opportunities of Targeted Drugs for Multiple Myeloma
Table 48. Key Market Challenges & Risks of Targeted Drugs for Multiple Myeloma
Table 49. Key Industry Trends of Targeted Drugs for Multiple Myeloma
Table 50. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 51. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Regions (2024-2029)
Table 52. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 53. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 54. Celgene Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 55. Celgene Targeted Drugs for Multiple Myeloma Product Offered
Table 56. Celgene Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 57. Celgene Main Business
Table 58. Celgene Latest Developments
Table 59. Exova Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 60. Exova Targeted Drugs for Multiple Myeloma Product Offered
Table 61. Exova Main Business
Table 62. Exova Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 63. Exova Latest Developments
Table 64. Natco Pharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 65. Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
Table 66. Natco Pharma Main Business
Table 67. Natco Pharma Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 68. Natco Pharma Latest Developments
Table 69. Intas Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 70. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
Table 71. Intas Pharmaceuticals Main Business
Table 72. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 73. Intas Pharmaceuticals Latest Developments
Table 74. Indiabulls Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 75. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 76. Indiabulls Pharmaceutical Main Business
Table 77. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 78. Indiabulls Pharmaceutical Latest Developments
Table 79. Cipla Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 80. Cipla Targeted Drugs for Multiple Myeloma Product Offered
Table 81. Cipla Main Business
Table 82. Cipla Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 83. Cipla Latest Developments
Table 84. Glenmark Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 85. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
Table 86. Glenmark Pharmaceuticals Main Business
Table 87. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 88. Glenmark Pharmaceuticals Latest Developments
Table 89. Dr Reddy's Laboratories Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 90. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
Table 91. Dr Reddy's Laboratories Main Business
Table 92. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 93. Dr Reddy's Laboratories Latest Developments
Table 94. Qilu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 95. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 96. Qilu Pharmaceutical Main Business
Table 97. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 98. Qilu Pharmaceutical Latest Developments
Table 99. Chia Tai-Tianqing Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 100. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
Table 101. Chia Tai-Tianqing Main Business
Table 102. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 103. Chia Tai-Tianqing Latest Developments
Table 104. Hanson Pharm Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 105. Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
Table 106. Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 107. Hanson Pharm Main Business
Table 108. Hanson Pharm Latest Developments
Table 109. Meidakang Huakang Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 110. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 111. Meidakang Huakang Pharmaceutical Main Business
Table 112. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 113. Meidakang Huakang Pharmaceutical Latest Developments
Table 114. Shandong Kongfu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 115. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 116. Shandong Kongfu Pharmaceutical Main Business
Table 117. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 118. Shandong Kongfu Pharmaceutical Latest Developments
Table 119. J&J Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 120. J&J Targeted Drugs for Multiple Myeloma Product Offered
Table 121. J&J Main Business
Table 122. J&J Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 123. J&J Latest Developments
Table 124. Takeda Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 125. Takeda Targeted Drugs for Multiple Myeloma Product Offered
Table 126. Takeda Main Business
Table 127. Takeda Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 128. Takeda Latest Developments
Table 129. Amgen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 130. Amgen Targeted Drugs for Multiple Myeloma Product Offered
Table 131. Amgen Main Business
Table 132. Amgen Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 133. Amgen Latest Developments
Table 134. Bristol Myers Squibb Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 135. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
Table 136. Bristol Myers Squibb Main Business
Table 137. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 138. Bristol Myers Squibb Latest Developments
Table 139. Abbvie Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 140. Abbvie Targeted Drugs for Multiple Myeloma Product Offered
Table 141. Abbvie Main Business
Table 142. Abbvie Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 143. Abbvie Latest Developments
Table 144. Seattle Genetics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 145. Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
Table 146. Seattle Genetics Main Business
Table 147. Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 148. Seattle Genetics Latest Developments
Table 149. Karyopharm Therapeutics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 150. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
Table 151. Karyopharm Therapeutics Main Business
Table 152. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 153. Karyopharm Therapeutics Latest Developments
Table 154. PDL BioPharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 155. PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
Table 156. PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 157. PDL BioPharma Main Business
Table 158. PDL BioPharma Latest Developments
Table 159. Roche Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 160. Roche Targeted Drugs for Multiple Myeloma Product Offered
Table 161. Roche Main Business
Table 162. Roche Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 163. Roche Latest Developments
Table 164. Sumitomo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 165. Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
Table 166. Sumitomo Main Business
Table 167. Sumitomo Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 168. Sumitomo Latest Developments
Table 169. Merck Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 170. Merck Targeted Drugs for Multiple Myeloma Product Offered
Table 171. Merck Main Business
Table 172. Merck Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 173. Merck Latest Developments
Table 174. Biogen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 175. Biogen Targeted Drugs for Multiple Myeloma Product Offered
Table 176. Biogen Main Business
Table 177. Biogen Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 178. Biogen Latest Developments
Table 179. Schering-Plough Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 180. Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
Table 181. Schering-Plough Main Business
Table 182. Schering-Plough Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 183. Schering-Plough Latest Developments
Table 184. Glaxo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 185. Glaxo Targeted Drugs for Multiple Myeloma Product Offered
Table 186. Glaxo Main Business
Table 187. Glaxo Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 188. Glaxo Latest Developments
Table 189. Chiron Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 190. Chiron Targeted Drugs for Multiple Myeloma Product Offered
Table 191. Chiron Main Business
Table 192. Chiron Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 193. Chiron Latest Developments
Table 1. Targeted Drugs for Multiple Myeloma Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Immunomodulator
Table 3. Major Players of Proteasome Inhibitors
Table 4. Major Players of Histone Deacetylase Inhibitors (HDACI)
Table 5. Major Players of Monoclonal Antibody
Table 6. Major Players of Other
Table 7. Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 9. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 10. Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 11. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 12. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 13. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2018-2023) & ($ Millions)
Table 14. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player (2018-2023)
Table 15. Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
Table 16. Targeted Drugs for Multiple Myeloma Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Targeted Drugs for Multiple Myeloma Market Size by Regions 2018-2023 & ($ Millions)
Table 20. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Regions (2018-2023)
Table 21. Global Targeted Drugs for Multiple Myeloma Revenue by Country/Region (2018-2023) & ($ millions)
Table 22. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Country/Region (2018-2023)
Table 23. Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023) & ($ Millions)
Table 24. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2018-2023)
Table 25. Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 26. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 27. Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 28. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 29. APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2018-2023) & ($ Millions)
Table 30. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)
Table 31. APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 32. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 33. APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 34. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 35. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023) & ($ Millions)
Table 36. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2018-2023)
Table 37. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 38. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 39. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 40. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 41. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Region (2018-2023) & ($ Millions)
Table 42. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)
Table 43. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Table 45. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Table 47. Key Market Drivers & Growth Opportunities of Targeted Drugs for Multiple Myeloma
Table 48. Key Market Challenges & Risks of Targeted Drugs for Multiple Myeloma
Table 49. Key Industry Trends of Targeted Drugs for Multiple Myeloma
Table 50. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 51. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Regions (2024-2029)
Table 52. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 53. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 54. Celgene Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 55. Celgene Targeted Drugs for Multiple Myeloma Product Offered
Table 56. Celgene Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 57. Celgene Main Business
Table 58. Celgene Latest Developments
Table 59. Exova Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 60. Exova Targeted Drugs for Multiple Myeloma Product Offered
Table 61. Exova Main Business
Table 62. Exova Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 63. Exova Latest Developments
Table 64. Natco Pharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 65. Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
Table 66. Natco Pharma Main Business
Table 67. Natco Pharma Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 68. Natco Pharma Latest Developments
Table 69. Intas Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 70. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
Table 71. Intas Pharmaceuticals Main Business
Table 72. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 73. Intas Pharmaceuticals Latest Developments
Table 74. Indiabulls Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 75. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 76. Indiabulls Pharmaceutical Main Business
Table 77. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 78. Indiabulls Pharmaceutical Latest Developments
Table 79. Cipla Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 80. Cipla Targeted Drugs for Multiple Myeloma Product Offered
Table 81. Cipla Main Business
Table 82. Cipla Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 83. Cipla Latest Developments
Table 84. Glenmark Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 85. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
Table 86. Glenmark Pharmaceuticals Main Business
Table 87. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 88. Glenmark Pharmaceuticals Latest Developments
Table 89. Dr Reddy's Laboratories Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 90. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
Table 91. Dr Reddy's Laboratories Main Business
Table 92. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 93. Dr Reddy's Laboratories Latest Developments
Table 94. Qilu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 95. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 96. Qilu Pharmaceutical Main Business
Table 97. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 98. Qilu Pharmaceutical Latest Developments
Table 99. Chia Tai-Tianqing Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 100. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
Table 101. Chia Tai-Tianqing Main Business
Table 102. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 103. Chia Tai-Tianqing Latest Developments
Table 104. Hanson Pharm Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 105. Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
Table 106. Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 107. Hanson Pharm Main Business
Table 108. Hanson Pharm Latest Developments
Table 109. Meidakang Huakang Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 110. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 111. Meidakang Huakang Pharmaceutical Main Business
Table 112. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 113. Meidakang Huakang Pharmaceutical Latest Developments
Table 114. Shandong Kongfu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 115. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
Table 116. Shandong Kongfu Pharmaceutical Main Business
Table 117. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 118. Shandong Kongfu Pharmaceutical Latest Developments
Table 119. J&J Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 120. J&J Targeted Drugs for Multiple Myeloma Product Offered
Table 121. J&J Main Business
Table 122. J&J Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 123. J&J Latest Developments
Table 124. Takeda Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 125. Takeda Targeted Drugs for Multiple Myeloma Product Offered
Table 126. Takeda Main Business
Table 127. Takeda Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 128. Takeda Latest Developments
Table 129. Amgen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 130. Amgen Targeted Drugs for Multiple Myeloma Product Offered
Table 131. Amgen Main Business
Table 132. Amgen Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 133. Amgen Latest Developments
Table 134. Bristol Myers Squibb Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 135. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
Table 136. Bristol Myers Squibb Main Business
Table 137. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 138. Bristol Myers Squibb Latest Developments
Table 139. Abbvie Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 140. Abbvie Targeted Drugs for Multiple Myeloma Product Offered
Table 141. Abbvie Main Business
Table 142. Abbvie Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 143. Abbvie Latest Developments
Table 144. Seattle Genetics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 145. Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
Table 146. Seattle Genetics Main Business
Table 147. Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 148. Seattle Genetics Latest Developments
Table 149. Karyopharm Therapeutics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 150. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
Table 151. Karyopharm Therapeutics Main Business
Table 152. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 153. Karyopharm Therapeutics Latest Developments
Table 154. PDL BioPharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 155. PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
Table 156. PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 157. PDL BioPharma Main Business
Table 158. PDL BioPharma Latest Developments
Table 159. Roche Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 160. Roche Targeted Drugs for Multiple Myeloma Product Offered
Table 161. Roche Main Business
Table 162. Roche Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 163. Roche Latest Developments
Table 164. Sumitomo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 165. Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
Table 166. Sumitomo Main Business
Table 167. Sumitomo Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 168. Sumitomo Latest Developments
Table 169. Merck Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 170. Merck Targeted Drugs for Multiple Myeloma Product Offered
Table 171. Merck Main Business
Table 172. Merck Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 173. Merck Latest Developments
Table 174. Biogen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 175. Biogen Targeted Drugs for Multiple Myeloma Product Offered
Table 176. Biogen Main Business
Table 177. Biogen Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 178. Biogen Latest Developments
Table 179. Schering-Plough Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 180. Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
Table 181. Schering-Plough Main Business
Table 182. Schering-Plough Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 183. Schering-Plough Latest Developments
Table 184. Glaxo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 185. Glaxo Targeted Drugs for Multiple Myeloma Product Offered
Table 186. Glaxo Main Business
Table 187. Glaxo Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 188. Glaxo Latest Developments
Table 189. Chiron Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
Table 190. Chiron Targeted Drugs for Multiple Myeloma Product Offered
Table 191. Chiron Main Business
Table 192. Chiron Targeted Drugs for Multiple Myeloma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 193. Chiron Latest Developments
LIST OF FIGURES
Figure 1. Targeted Drugs for Multiple Myeloma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Targeted Drugs for Multiple Myeloma Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2022)
Figure 8. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type in 2022
Figure 10. Targeted Drugs for Multiple Myeloma in Hospital
Figure 11. Global Targeted Drugs for Multiple Myeloma Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Targeted Drugs for Multiple Myeloma in Drug Center
Figure 13. Global Targeted Drugs for Multiple Myeloma Market: Drug Center (2018-2023) & ($ Millions)
Figure 14. Targeted Drugs for Multiple Myeloma in Clinic
Figure 15. Global Targeted Drugs for Multiple Myeloma Market: Clinic (2018-2023) & ($ Millions)
Figure 16. Targeted Drugs for Multiple Myeloma in Other
Figure 17. Global Targeted Drugs for Multiple Myeloma Market: Other (2018-2023) & ($ Millions)
Figure 18. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application in 2022
Figure 19. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player in 2022
Figure 20. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Regions (2018-2023)
Figure 21. Americas Targeted Drugs for Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 22. APAC Targeted Drugs for Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 23. Europe Targeted Drugs for Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 24. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 25. Americas Targeted Drugs for Multiple Myeloma Value Market Share by Country in 2022
Figure 26. United States Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 27. Canada Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 28. Mexico Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 29. Brazil Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 30. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region in 2022
Figure 31. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Type in 2022
Figure 32. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Application in 2022
Figure 33. China Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 34. Japan Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 35. Korea Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 36. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 37. India Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 38. Australia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 39. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country in 2022
Figure 40. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Figure 41. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Figure 42. Germany Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 43. France Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 44. UK Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 45. Italy Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 46. Russia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 47. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)
Figure 48. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Figure 49. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Figure 50. Egypt Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 51. South Africa Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 52. Israel Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 53. Turkey Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 54. GCC Country Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 55. Americas Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 56. APAC Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 57. Europe Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 58. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 59. United States Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 60. Canada Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 61. Mexico Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 62. Brazil Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 63. China Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 64. Japan Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 65. Korea Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 66. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 67. India Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 68. Australia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 69. Germany Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 70. France Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 71. UK Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 72. Italy Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 73. Russia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 74. Spain Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 75. Egypt Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 76. South Africa Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 77. Israel Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 78. Turkey Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 79. GCC Countries Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 80. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Type (2024-2029)
Figure 81. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Targeted Drugs for Multiple Myeloma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Targeted Drugs for Multiple Myeloma Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2022)
Figure 8. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type in 2022
Figure 10. Targeted Drugs for Multiple Myeloma in Hospital
Figure 11. Global Targeted Drugs for Multiple Myeloma Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Targeted Drugs for Multiple Myeloma in Drug Center
Figure 13. Global Targeted Drugs for Multiple Myeloma Market: Drug Center (2018-2023) & ($ Millions)
Figure 14. Targeted Drugs for Multiple Myeloma in Clinic
Figure 15. Global Targeted Drugs for Multiple Myeloma Market: Clinic (2018-2023) & ($ Millions)
Figure 16. Targeted Drugs for Multiple Myeloma in Other
Figure 17. Global Targeted Drugs for Multiple Myeloma Market: Other (2018-2023) & ($ Millions)
Figure 18. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application in 2022
Figure 19. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player in 2022
Figure 20. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Regions (2018-2023)
Figure 21. Americas Targeted Drugs for Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 22. APAC Targeted Drugs for Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 23. Europe Targeted Drugs for Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 24. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2018-2023 ($ Millions)
Figure 25. Americas Targeted Drugs for Multiple Myeloma Value Market Share by Country in 2022
Figure 26. United States Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 27. Canada Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 28. Mexico Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 29. Brazil Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 30. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region in 2022
Figure 31. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Type in 2022
Figure 32. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Application in 2022
Figure 33. China Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 34. Japan Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 35. Korea Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 36. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 37. India Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 38. Australia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 39. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country in 2022
Figure 40. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Figure 41. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Figure 42. Germany Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 43. France Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 44. UK Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 45. Italy Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 46. Russia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 47. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)
Figure 48. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
Figure 49. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
Figure 50. Egypt Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 51. South Africa Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 52. Israel Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 53. Turkey Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 54. GCC Country Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 ($ Millions)
Figure 55. Americas Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 56. APAC Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 57. Europe Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 58. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 59. United States Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 60. Canada Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 61. Mexico Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 62. Brazil Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 63. China Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 64. Japan Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 65. Korea Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 66. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 67. India Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 68. Australia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 69. Germany Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 70. France Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 71. UK Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 72. Italy Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 73. Russia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 74. Spain Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 75. Egypt Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 76. South Africa Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 77. Israel Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 78. Turkey Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 79. GCC Countries Targeted Drugs for Multiple Myeloma Market Size 2024-2029 ($ Millions)
Figure 80. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Type (2024-2029)
Figure 81. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Application (2024-2029)
